Cargando…

P1643: EFFICACY OF RECOMBINANT HUMANTHROMBOPOIETIN ON CHILDREN IMMUNE THROMBOCYTOPENIA AND ITS INFLUENCING FACTORS

Detalles Bibliográficos
Autores principales:	Ma, J., CHEN, Z., GU, H., WU, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430582/ http://dx.doi.org/10.1097/01.HS9.0000849428.11901.5a

Ejemplares similares

Phenotypic Characterization of the c.1679+1643G>T (1811+1643G>T) Mutation in Hispanic Cystic Fibrosis Patients
por: Fanous, Hani K., et al.
Publicado: (2018)

P1643: FIBRIN CLOT PROPERTIES IDENTIFY PATIENTS THAT BENEFIT FROM CATHETER-DIRECTED THROMBOLYSIS: A POST HOC ANALYSIS OF THE CAVA TRIAL
por: Iding, Aaron F.J., et al.
Publicado: (2023)

1643. A scoping review of pediatric latent tuberculosis care cascades: Initial steps are lacking
por: Campbell, Jeffrey, et al.
Publicado: (2020)

P1615: ASPECTS OF THE THERAPY SELECTION FOR IMMUNE THROMBOCYTOPENIA IN CHILDREN
por: Khoduleva, Sviatlana, et al.
Publicado: (2023)

1643P Knowledge and attitude of cancer patients towards COVID-19 pandemic: A study from Pakistan
por: Yaqub, S., et al.
Publicado: (2021)

Comment on Expression of Concern Cell Cycle Volume 12, Issue 10; p. 1643
Publicado: (2013)

P1593: DECIPHERING UNIQUE HETEROGENEITY AND EFFICACY DIFFERENCES IN IMMUNE THROMBOCYTOPENIA AT THE SINGLE-CELL LEVEL
por: Xu, Min, et al.
Publicado: (2023)

Activated recombinant factor VII in management of bleeding in patients with thrombocytopenia
por: Shulutko, E, et al.
Publicado: (2006)

P1653: CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC
por: Cai, X., et al.
Publicado: (2022)

P1669: AUTOANTIBODY-MEDIATED PLATELET DESIALYLATION IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
por: Schramm, T., et al.
Publicado: (2022)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

Effects of the Small Molecule HERG Activator NS1643 on Kv11.3 Channels
por: Bilet, Arne, et al.
Publicado: (2012)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

P1655: PERSONALIZED MACHINE-LEARNING-BASED PREDICTION FOR CRITICAL IMMUNE THROMBOCYTOPENIA BLEEDS: A NATIONWIDE DATA STUDY
por: An, Z.-Y., et al.
Publicado: (2022)

P1625: CLINICAL AND LABORATORY CHARACTERISTICS OF ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN EASTERN AUSTRIA
por: Rast, Jasmin, et al.
Publicado: (2023)

P1611: EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA IN A CHINESE ADULT POPULATION：A MULTICENTER, RANDOMIZED PHASE III TRIAL
por: Mei, Heng, et al.
Publicado: (2023)

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, F., et al.
Publicado: (2022)

1643 Clostridium difficile Infection Related Emergency Department Visits in the United States 2006-2009
por: Deshpande, Abhishek, et al.
Publicado: (2014)

P1651: HDAC3 RS2530223 IS ASSOCIATED WITH INCREASED SUSCEPTIBILITY AND SEVERITY OF PRIMARY IMMUNE THROMBOCYTOPENIA
por: Wang, S.
Publicado: (2022)

P1595: ACTIVATION OF CHAPERONE-MEDIATED AUTOPHAGY REDUCES NLRP3 AND PLATELET CLEARANCE IN IMMUNE THROMBOCYTOPENIA
por: Xu, Yitong, et al.
Publicado: (2023)

P1601: PREDICTING THE RESPONSE TO SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA (ITP): A MULTI-CENTRIC PILOT STUDY
por: Zoletto, Simone, et al.
Publicado: (2023)

1643. Journey Mapping Penicillin Allergies in Children: Parental Experiences, Care Gaps, and Suggestions Offered by Parents to Address Unmet Needs
por: Carter, Eileen J, et al.
Publicado: (2023)

P1597: COMPLEMENT ACTIVATION ON MSCS REGULATE MEGAKARYOPOIESIS BY INTERLEUKIN-35 AND ITS RECEPTOR IL-12RΒ2/GP130 IN IMMUNE THROMBOCYTOPENIA
por: Zhu, Xiaolu, et al.
Publicado: (2023)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

A Bibliography of Two Oxford Physiologists: Richard Lower, 1631-1691, and John Mayow, 1643-1679
Publicado: (1935)

P1596: EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL
por: Zhou, Hu, et al.
Publicado: (2023)

P1654: COMPLEMENT ACTIVATION REGULATES PLATELET HOMEOSTASIS BY ARRESTING THE ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN-35 IN IMMUNE THROMBOCYTOPENIA
por: Gui, R.-Y., et al.
Publicado: (2022)

P1636: PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).
por: Jansen, A. G., et al.
Publicado: (2022)

P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE
por: Santano, Ana María Mena, et al.
Publicado: (2023)

P1591: IMPACT OF COVID-19 ON THE EVOLUTION OF PRE-EXISTING PRIMARY IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE OBSERVATIONAL STUDY
por: Fu, Haixia, et al.
Publicado: (2023)

P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL
por: Zhao, Peng, et al.
Publicado: (2023)

P1600: USE OF RITUXIMAB PLUS STANDARD OF CARE FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Eshaghpour, Ali, et al.
Publicado: (2023)

The Effect of Lactobacillus acidophilus PTCC 1643 on Cultured Intestinal Epithelial Cells Infected with Salmonella enterica serovar Enteritidis
por: Moshiri, Mona, et al.
Publicado: (2017)

P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
por: Cooper, Nichola, et al.
Publicado: (2023)

P1647: CONTRIBUTION OF NEXT GENERATION FLOW (NGF) CYTOMETRY IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UTILITY FOR THE DIFFERENTIAL DIAGNOSIS WITH MYELODYSPLASTIC SYNDROMES
por: Gonzalez-Lopez, T. J., et al.
Publicado: (2022)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023)

P1676: COVID VACCINE INDUCED IMMUNO THROMBOCYTOPENIA AND THROMBOSIS - OBSERVATIONAL STUDY
por: Gopaluni, S., et al.
Publicado: (2022)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
por: Mei, J., et al.
Publicado: (2022)

P1634: EFFICACY AND SAFETY OF ELTROMBOPAG IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION PATIENTS WITH THROMBOCYTOPENIA（HBV-TP）: A PROSPECTIVE, MULTI-CENTER, SINGLE ARM, PHASE II TRAIL
por: Chen, Y., et al.
Publicado: (2022)

P1641: ELTROMBOPAG TREATMENT, OUTCOMES AFTER DISCONTINUATION IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA, AND EXPLORATION OF POTENTIAL PREDICTIVE FACTORS: A REAL-WORLD CLINICAL EXPERIENCE
por: Liu, X., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rjbj1ek7nqmg1u4c66ts6q0kqq